Monocyte-to-lymphocyte ratio is a promising biomarker in patients initially receiving hemodialysis

单核细胞与淋巴细胞比值是初次接受血液透析患者的一种很有前景的生物标志物。

阅读:2

Abstract

AIM: Inflammation is very common among dialysis patients and can lead to an increase in morbidity and mortality. Monocyte-to-lymphocyte ratio (MLR) can serve as a reliable predictor of long-term survival in hemodialysis patients. However, few studies have addressed the role of MLR in patients initially receiving hemodialysis (within 3 months). In this study, we aimed to examine the association between MLR and the risk of cardiovascular and all-cause mortality in patients initially receiving hemodialysis. METHODS: In this study, a total of 216 patients newly receiving hemodialysis for at least 3 months were recruited. The associations between MLR and cardiovascular diseases (CVD) and all-cause mortality were assessed by multivariable Cox models. RESULTS: A total of 216 patients were included (mean age 57.65 ± 15.68 years, 42.13% male patients). Patients were divided into the low MLR group (<0.49) and the high MLR group (≥0.49). The levels of neutrophil and serum iron and the number of deaths were significantly higher in the high MLR group (P < 0.05). Spearman's analysis showed that MLR was positively correlated with BUN (R = 0.210, P = 0.002), WBC (R = 0.178, P = 0.009), and neutrophil (R = 0.237, P < 0.001). Kaplan-Meier analysis showed that patients in the low MLR group present longer survival (64.08 ± 2.30 vs. 51.07 ± 3.12 months, P < 0.001). Multivariate Cox regression analysis showed that age, diabetes, and MLR (all P < 0.05) were factors significantly associated with a higher risk of CVD and all-cause mortality. CONCLUSIONS: Our results showed that high MLR values are an independent risk factor for CVD and all-cause mortality in patients initially receiving hemodialysis, especially in the elderly and those with a history of diabetes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。